33rd International Vicenza Course on Critical Care Nephrology
|
Opening Ceremony
|
- Opening Remarks – C. Ronco
- Welcome from Italian Society of Nephrology – R. Coppo
- International Society for Hemodialysis award for best abstracts –M. Misra
- Invited Opening Lecture: The future of health care reform – A.Milburn
|
|
Session 1: Epidemiology of AKI
|
- The Search for a Standard of Care – J.Hegbrant
- Risk Management: working for safety – J.Bosch
- The Medical Director: working efficacy – A. Nissenson
- Delivering optimal quality of care managing all stakeholders’ interests – A.Stopper
|
|
Session 3: RRT in AKI and Critical Illness
|
- Uric acid: metabolic and cardiovascular risk – A. Covic
- Micro inflammation and endothelial damage in CKD and hemodialysis – P. Aljama
- Biomarkers of chronic inflammatory state in uremia and CVD – V. Panichi
- The burdne of cardiovascular risk in CKD and dialysis patients (CRS Type 4) – A.House
- Disparities of treatment for ACS and Heart Failure in CKD patients – P. Mc Cullough
|
|
Session 4: Multiple Organ Support Therapies
|
- Is Dialysis Catheter harming the patient? – M. Kuhlmann
- The evils of intradialytic sodium loading – P. Kotanko
- Is AV fistula harming the patient? – R. Amerling
- The concept of wet and dry BNP – A. Maisel
- The wonders of ultrasonography – M. Pittiruti
|
|
Session 5: Biomarkers of AKI
|
- Recent trials on Hemodiafiltration – F.Locatelli
- The treatment of HCV with Affinity Plasmapheresis on Dialysis Machines – R. Kenley
- From High flux to super high flux – M. Kuhlmann
- Antioxidant dialytic approach with vitamin E coated membranes – F. Nalesso
- Light chain removal: HCO membranes – A. Santoro
|
|
Session 6: AKI – Pathophysiology, Prevention, Recovery, Progression
|
- Statins and lipid lowering strategies in cardio-renal patients – S.Bianchi
- Results from recent trials – D. de Zeeuw
- Factors determining insulin resistance in hemodialysis patients – A. Ikizler
- The spectrum of metabolic alterations in dialysis – M. Misra
- Lipid disorders in uremia and dialysis – W.Keane
- New insights on inflammation and protein energy wasting in CKD – P.Stenvinkel
|
|
Session 7: CardioRenal Crosstalk
|
- VDR Activators: clinical outcomes – A. Covic
- Restoring the physiology of VDR activation and the concept of selectivity – M. Cozzolino
- The impact of paricalcitol on CKD progression measured by albuminuria (The VITAL study) – D. de Zeeuw
- The impact of paricalcitol on LVH (The PRIMO study) – M. Cozzolino
- VDRA: Implications to daily practice – D. Warnock
|
|
Session 8: Fluid management
|
- Blood Volume & Biofeedback – A.Santoro
- Body composition and Heart rate variability to achieve dry weight and tolerance – F. Nalesso
- Extracorporeal Ultrafiltration for congestive heart failure patients – M.R. Costanzo
- BIVA + BNP in the emergency room – S. Di Somma
|
|
Session 9: Critical Care Nephrology Issues
|
- AKI Biomarkers and endpoints for Clinical Trials – P. Murray
- AKI: can we prevent it? – P. Mc Cullough
- Impact of AKI on CKD and its progression – M.Okusa
- Special Lecture: Acute Kidney Injury and its management – J. Kellum
|
|
Session 10: New Horizons in AKI and CRRT
|
- Financial implications from application of wearable technology – R. Greenwood
- Clinical benefits of a wearable approach – A. Davenport
- The WAK project: where are we? – V. Gura
- Wearable dialysis: what is missing – H.D. Polaschegg
- Wearable ultrafiltration for heart failure – C. Ronco
|
|
Session 11: Anemia and its management
|
- New ESAs and new Iron formulations – F. Locatelli
- Impact of dialytic technique on anemia – V. Panichi
- Anemia Trials in CKD and Clinical practice: Refining the approach to ESA’s use – A. De Francisco
- Anemia and Hypoalbuminemia as Prognostic Indicators in HD: Fact or Artefact? – R. Amerling
- Anemia in HD and PD: similar treatments? – J. Burkart
- The Cardio Renal Anemia syndrome – S. von Heahling
|
